Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients

Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients

Abstract Background and Purpose Gut microbes play an important role in the occurrence of lung cancer, immunotherapy, and chemotherapy. In this study, we analyzed the characteristics of gut microbes in patients with lung cancer and investigated the effect of gut microbes on anti‐PD‐1 therapy combined...

Full description

Bibliographic Details
Main Authors:	Honghui Zhao, Dan Li, Jiayin Liu, Xinliang Zhou, Jing Han, Long Wang, Zhisong Fan, Li Feng, Jing Zuo, Yudong Wang
Format:	Article
Language:	English
Published:	Wiley 2023-03-01
Series:	Cancer Medicine
Subjects:	biomarker chemotherapy gut microbes immunotherapy non‐small cell lung cancer
Online Access:	https://doi.org/10.1002/cam4.5312

Similar Items

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
by: Wen Li, et al.
Published: (2022-07-01)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
by: Yaping Long, et al.
Published: (2022-02-01)

Cepharanthine Hydrochloride Improves Cisplatin Chemotherapy and Enhances Immunity by Regulating Intestinal Microbes in Mice
by: Pengjun Zhou, et al.
Published: (2019-06-01)

Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study
by: Yinkui Wang, et al.
Published: (2022-12-01)

Adjuvant chemotherapy combined with immunotherapy in patients with cholangiocarcinoma after radical resection
by: Xiao‐hui Li, et al.
Published: (2023-12-01)

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms
by: Huihui Yin, et al.
Published: (2021-11-01)

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC
by: Yu Fu, et al.
Published: (2023-11-01)

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
by: Weiguang Gu, et al.
Published: (2023-11-01)

Gut microbes as medical signature for the effectiveness of immunotherapy in patients with advanced non‐small cell lung cancer
by: Adane Adugna, et al.
Published: (2024-02-01)

Editorial: Recombinant microbes-mediated cancer immunotherapy
by: Stephen Wechman, et al.
Published: (2024-02-01)

Genomic and ecological approaches to identify the Bifidobacterium breve prototype of the healthy human gut microbiota
by: Chiara Argentini, et al.
Published: (2024-02-01)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
by: Alessandro Inno, et al.
Published: (2023-02-01)

Immunotherapy and Chemotherapy Versus Sleep Disturbances for NSCLC Patients
by: Paul Zarogoulidis, et al.
Published: (2023-02-01)

Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
by: Marc Mansour, et al.
Published: (2011-08-01)

Case Report: Clinical application of immunotherapy-based combination regimen in primary osteosarcoma of the uterus
by: Jing Yang, et al.
Published: (2023-07-01)

Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer
by: Lei Zhang, et al.
Published: (2022-10-01)

Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy
by: Patrycja Śliwa-Tytko, et al.
Published: (2022-05-01)

Denosumab Regulates Gut Microbiota Composition and Cytokines in Dinitrobenzene Sulfonic Acid (DNBS)-Experimental Colitis
by: Azin Khafipour, et al.
Published: (2020-06-01)

Effects of chemotherapy and immunotherapy on microbial diversity in TME and engineered bacterial-mediated tumor therapy
by: Heng Zheng, et al.
Published: (2023-02-01)

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
by: Lulu Lv, et al.
Published: (2022-08-01)

SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer
by: Siyuan Weng, et al.
Published: (2022-07-01)

High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy
by: Wenxiao Jia, et al.
Published: (2023-02-01)

Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
by: Eleni Skavatsou, et al.
Published: (2021-04-01)

BCL2A1 and CCL18 Are Predictive Biomarkers of Cisplatin Chemotherapy and Immunotherapy in Colon Cancer Patients
by: Taohua Yue, et al.
Published: (2022-02-01)

Targeting PD‐L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy Combined with Immunotherapy
by: Xing Hu, et al.
Published: (2023-12-01)

Development of an Aging-Related Gene Signature for Predicting Prognosis, Immunotherapy, and Chemotherapy Benefits in Rectal Cancer
by: Yangyang Wang, et al.
Published: (2022-01-01)

Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors
by: Zhengfeng Zhang, et al.
Published: (2023-07-01)

Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
by: Lingdi Zhao, et al.
Published: (2020-04-01)

Editorial: Chemosensitizing effect of natural products against cancers: Applications in enhancing chemotherapy and immunotherapy
by: Nand K. Roy, et al.
Published: (2022-08-01)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
by: Yunsong Liu, et al.
Published: (2023-01-01)

Chemotherapy: A partnership with immunotherapy in non‐small cell lung cancer
by: Ana Sofia Mendes, et al.
Published: (2023-02-01)

Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer
by: Joanna Jagieła, et al.
Published: (2021-04-01)

Retrospective analysis of the efficacy of cytokine‐induced killer cell immunotherapy combined with first‐line chemotherapy in patients with metastatic colorectal cancer
by: Qiu‐Zhong Pan, et al.
Published: (2020-01-01)

Research progress on the pharmacological effects of matrine
by: Yanan Sun, et al.
Published: (2022-08-01)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
by: Lan-Lan Pang, et al.
Published: (2023-01-01)

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy
by: Shanshan Zhen, et al.
Published: (2024-02-01)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
by: Min Fang, et al.
Published: (2023-01-01)

Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series
by: Elizabeth M. Gaughan, et al.
Published: (2022-04-01)

Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review
by: Peter L. Miller, et al.
Published: (2020-09-01)

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
by: Yi Zheng, et al.
Published: (2019-07-01)